BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Josh Carpenter

  Josh Carpenter, D.Phil., is the president and CEO of Southern Research.
• 

  Diabetes

  Novo Refuses to Give Up on Insulin Icodec, Eyes Combo Filing With Semaglutide

  By the end of the year, Novo Nordisk intends to make a regulatory filing for the combination of its icodec and semaglutide, keeping its once-weekly insulin program afloat.

  August 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  Galderma’s IL-31 Injection Wins FDA Approval for Skin Disorder Prurigo Nodularis

  The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.

  August 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Q2 Recap: Smooth Sailing for Some, but COVID Cliff and Vaccine Issues Thwart Others

  While some biopharma companies beat expectations, others fell short for various reasons, with some deciding to return or axe assets.

  August 13, 2024

   · 

  6 min read

   · 

  Tyler Patchen
• 

  Mergers & acquisitions

  Crown Laboratories to Buy Botox Rival Revance Therapeutics for $924M

  The acquisition announced Monday will give Crown access to Revance’s Daxxify, a competitor to AbbVie’s Botox, which is indicated for frown lines and for cervical dystonia.

  August 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  psychedelics

  Atai Touts Early Data on Psychedelic Depression Drug, Plans Phase II Trial

  On the heels of last week’s FDA rejection of Lykos’ MDMA-assisted PTSD therapy, Atai announced Tuesday positive preliminary results for its DMT-based treatment for depression from a Phase Ib study.

  August 13, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Legal

  Novartis Loses Court Case to Block Entresto Generics After FDA Denies Petition

  On the heels of the FDA’s denial of its petition, a Delaware district court on Monday handed Novartis another loss in its efforts to keep the market free of Entresto copycats.

  August 13, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Boundless Bio Announces ‘Modest Reduction’ to San Diego Workforce

  The layoffs are intended to help provide an operating runway into the fourth quarter of 2026.

  August 13, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• Press Releases

  Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

  August 13, 2024

   · 

  9 min read
• Press Releases

  Extendicare Announces 2024 Second Quarter Results

  August 13, 2024

   · 

  15 min read